A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending exotilimab or belumosidil for lung involvement, any of the three oral agents for ...

Researchers from Instituto de Investigación Sanitaria Hospital Universitario de La Princesa and collaborators have developed nanoparticles loaded with poly(I:C) and used them to prime monocyte-derived ...

Treating rare diseases can be complicated at the best of times, and it gets even more complicated when different patients ...

They are rapidly secreted by activated monocytes or neutrophils, which are abundant in inflamed synovial tissue. HSPs are involved in the crosstalk between innate and adaptive immune systems, ...

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to ...

Treating rare diseases can be complicated at the best of times, and it gets even more complicated when different patients ...

Nuvectis Pharma's oncology pipeline shows promise, but phase 1 trials and high biotech risk warrant caution. Click here to ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...

"In psoriatic arthritis, joint damage can begin early and progress quickly if left untreated, significantly impacting a patient's ability to move, work and maintain independence," said Philip J ...

Researchers have developed new CAR-T cells to target malignant tumors. Their method targeted a protein found in high amounts on many types of cancer cells (Eva1) and successfully eliminated tumors in ...

Treating rare diseases can be complicated at the best of times, and it gets even more complicated when different patients with the same ...